Business Description
Translate Bio Inc
NAICS : 325412
SIC : 2833
Description
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.53 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | 1.12 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.11 | |||||
| Beneish M-Score | 3.05 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | 54.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -14.75 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 53.41 | |||||
| 12-1 Month Momentum % | 168.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.8 | |||||
| Quick Ratio | 8.8 | |||||
| Cash Ratio | 8.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 18.52 | |||||
| Net Margin % | 17.97 | |||||
| ROE % | 11.26 | |||||
| ROA % | 5 | |||||
| ROIC % | 16.58 | |||||
| ROC (Joel Greenblatt) % | 55.08 | |||||
| ROCE % | 5.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 73.83 | |||||
| PE Ratio without NRI | 73.83 | |||||
| PS Ratio | 12.87 | |||||
| PB Ratio | 6.82 | |||||
| Price-to-Tangible-Book | 8.9 | |||||
| Price-to-Free-Cash-Flow | 9.68 | |||||
| Price-to-Operating-Cash-Flow | 9.51 | |||||
| EV-to-EBIT | 53.13 | |||||
| EV-to-EBITDA | 42.75 | |||||
| EV-to-Revenue | 9.84 | |||||
| EV-to-FCF | 7.48 | |||||
| Price-to-Graham-Number | 5.4 | |||||
| Price-to-Net-Current-Asset-Value | 12.54 | |||||
| Price-to-Net-Cash | 16.1 | |||||
| Earnings Yield (Greenblatt) % | 1.88 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TBIO
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 225.086 | ||
| EPS (TTM) ($) | 0.506 | ||
| Beta | 0 | ||
| Volatility % | 113.1 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.403571 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 168.61 | ||
| 52-Week Range ($) | 11.91 - 37.985 | ||
| Shares Outstanding (Mil) | 75.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Translate Bio Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Translate Bio Inc Analysis
Share your researchHeadlines
See More
No news.